Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Abnova Taiwan Corp. (4133) AI Stock Analysis

TW:4133

Abnova Taiwan Corp.

(TWSE:4133)

Select Model
Rating:42Neutral
Price Target:TWD 19.00â–¼(-4.28% Downside)
Action:initiatedcoverage
Date:11/10/26

The overall score is heavily pressured by a severe operational and cash flow decline, which overshadows an exceptionally strong balance sheet. Bearish technical trends and an unattractive valuation further weigh on the outlook. The primary risk is the company's inability to reverse its revenue and profit deterioration before it erodes its solid capital base.

Positive Factors
Very Low LeverageAbnova’s very low leverage and equity-heavy capital structure reduce solvency risk and preserve financial flexibility. This gives the company greater capacity to withstand operating volatility, fund product development, and respond to weaker trading conditions without heavy debt-service pressure.
Negative Factors
Multi-Year Revenue DeclinePersistent revenue contraction across several years points to weakening demand, customer activity, or commercial execution rather than a single temporary fluctuation. Continued top-line decline can reduce operating leverage, constrain investment capacity, and make a durable return to earnings growth more difficult.

Abnova Taiwan Corp. (4133) vs. SPDR S&P 500 ETF (SPY)

-20%-10%0%10%20%30%TW:4133-14.89%SPY+13.89%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
TWD 1.21B
Dividend Yield
0.56%
Average Volume (3M)
137.19K
Price to Earnings (P/E)
27.0
Beta (1Y)
0.47
Revenue Growth
-4.19%
EPS Growth
―
Country
TW
Employees
110
Sector
General
Sector Strength
55
Industry
Biotechnology

Abnova Taiwan Corp. Business Overview & Revenue Model

Company Description

Abnova (Taiwan) Corporation specializes in the development and distribution of a comprehensive range of recombinant proteins and antibodies. The company's extensive product portfolio caters to diverse research and diagnostic applications, featuring s...

Abnova Taiwan Corp. Financial Statement Overview

Summary

Financial performance is deeply polarized. The balance sheet is a fortress with negligible debt (D/E 0.015), but this is overshadowed by a severe operational collapse. Revenue is declining, profitability has swung to a net loss, and operating cash flow has turned negative. The strong capital base provides a buffer, but the rapid earnings deterioration is a critical risk.

Income Statement

18Very Negative

Balance Sheet

85Very Positive

Cash Flow

10Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue345.45M351.30M355.26M382.05M411.76M451.49M
Gross Profit155.52M139.87M163.26M173.91M201.43M197.34M
EBITDA57.41M45.66M103.47M81.21M129.60M79.79M
Net Income44.87M-1.14M61.61M43.68M74.84M28.37M
Balance Sheet
Total Assets1.35B1.33B1.40B1.36B1.37B1.28B
Cash, Cash Equivalents and Short-Term Investments406.17M378.71M448.55M423.51M367.91M307.27M
Total Debt17.06M18.50M24.01M7.71M10.88M8.18M
Total Liabilities79.68M70.74M91.65M69.42M82.83M71.29M
Stockholders Equity1.27B1.26B1.31B1.29B1.29B1.21B
Cash Flow
Free Cash Flow44.76M-7.73M43.13M47.33M118.51M92.04M
Operating Cash Flow51.47M-4.19M50.85M76.22M132.37M92.88M
Investing Cash Flow-9.63M-6.22M19.78M36.79M-13.37M960.00K
Financing Cash Flow-60.04M-60.01M-49.09M-55.62M-61.40M-43.80M

Abnova Taiwan Corp. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

TW:4133 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
TW:4161TW:416161NeutralTWD 1.22B11.45―3.32%7.54%35.87%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
TW:1796TW:179652NeutralTWD 1.14B162.76―2.50%7.05%―
TW:4133TW:413342NeutralTWD 1.20B27.03―0.56%-4.19%―
TW:6578TW:657842NeutralTWD 1.21B-51.66―2.37%21.50%-5.51%

* General Sector Average

Performance Comparison

0%100%200%300%TW:4133TW:1796TW:4161TW:6564TW:6578TW:7530Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
TW:4133 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
TW:4133Abnova Taiwan Corp.19.85-3.62-15.43%
TW:1796GeneFerm Biotechnology Co. Ltd.27.60-19.53-41.44%
TW:4161Bioptik Technology, Inc.20.90-4.70-18.36%
TW:6564Enimmune corporation14.75-6.37-30.15%
TW:6578Dabomb Protein Biotech Corporation16.70-2.95-15.01%
TW:7530Forward Science Corp.29.0515.46113.81%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 10, 2026